AdARRC™
  • Call Us: +971 2 245 0058
  • Email Us : info@adarrc.org
  • Home
  • About Us
  • Committee
  • Future Dates of AdARRC™
  • History
    • AdARRC Academy™
    • AdARRC Summit™
    • Previous Speakers of AdARRC™
  • Annual Initiatives
    • Best Image Competition
    • Nominate a Trainee Winner
  • Sponsorship
×

Combination of baricitinib and remdesivir reduces recovery time in patients hospitalized with COVID-19 pneumonia

AdARRC™ March 29, 2021 Monday Weekly Update
 Combination of baricitinib and remdesivir reduces recovery time in patients hospitalized with COVID-19 pneumonia

Question

Does the combination of baricitinib and remdesivir improve outcomes in patients hospitalized with COVID-19?

Conclusion

Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. Published online December 11, 2020. doi: 10.1056/NEJMoa2031994.

Reference

Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. Published online December 11, 2020. doi: 10.1056/NEJMoa2031994.

Share This Post!

BMD testing: one and done

Previous post

Colchicine reduces myocardial infarction and revascularization in patients with established coronary disease (LoDoCo2)

Next post

AdARRC™

Organising Secretariat

  • K.I.T. Group Middle East FZ LLC
  • Yas Creative Hub, Tower 1
  • P.O. Box: 77893
  • Abu Dhabi, United Arab Emirates

+ 971 2 245 0058
+ 971 55 295 0283
info@adarrc.org
Monday – Friday: 9:00 AM – 06:00 PM (GMT+4)

 

© 2026 AdARRC™. All rights reserved